Company Update: SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM | Learn More
Logo yposkesi
waves image

Meet our team at the ISCT: May 31-June 2, 2023 in Paris, France.

The event

The ISCT conference will take place May 31 – June 2nd 2023 at the Palais des Congrès of Paris in Paris, France.

Learn more about the event

Our team

Meet our team during the event: 

Stop by our booth #64 to meet our team during the ISCT conference and learn more about our extended services to bring your cell and gene therapies to life… From process development up to commercial launch, Yposkesi is the full-service CDMO of choice, working by your side, to meet your timelines and budget.

Poster presentation

Efficient transduction of T cells using a suspension-based lentiviral vector system

Aude Parcelier, Aniya Larbi, Emilie Neveu, Adrien Auffret Cariou, Cédrick Rousseaux, and Sabine Charrier.

Gene transfer technology using lentiviral vectors (LV) is one of the most promising therapeutic approaches for cancer immunotherapy (CAR-T or TCR cells). However, an important manufacturing challenge is the industrialization of lentiviral vectors, especially given the potential larger quantity/volume requirements for these new applications. Therefore, we have developed a new suspension scalable lentiviral vectors manufacturing process and have conducted studies to evaluate lhe tranduction efficiency in T cells using lentiviral vectors produced by this new system.


Posters are located in the Poster Hall during the ISCT conference, the presentation of our poster will be held by Aude Parcelier during the Poster Reception 2 on June 1 from 6:00 PM to 7:30 PM CEST.
Poster ID is 869.

Learn more about our newly launched Lentiviral Vector Manufacturing Platform: LentiSure™!

At the beginning of April 2023, Yposkesi launched its new Lentiviral Vector Manufacturing Platform, LentiSure.

LentiSure is providing the premium quality grade lentiviral vectors you need to assure your clinical development and commercial cell and gene therapy pipeline. LentiSure’s robust, scalable, and plug & play-optimized processes enable you to accelerate the time to market of your cell and gene therapies and facilitate better patient outcomes. You obtain a safe and effective product through LentiSure’s high productivity and established analytical methods. LentiSure is the choice for high titers, transduction efficiency, reliability, and accessing scalable production processes with optimized purification techniques.


Learn more about LentiSure
Created by Yerokhoff Kostyiantine